Best Inrebic (Fedratinib) Medicine in India

Inrebic (Fedratinib) is a targeted anticancer medicine used to treat adults with intermediate-2 or high-risk primary myelofibrosis (MF), post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis. It belongs to a group of medicines called Janus kinase (JAK) inhibitors and works mainly by blocking abnormal JAK2 signaling involved in the growth of blood cells and development of myelofibrosis.

Inrebic (Fedratinib) should be taken exactly as prescribed by your doctor, usually once daily with or without food. Taking it with a meal may help reduce nausea. Swallow the capsule whole with water and do not crush, chew, or open it. Your doctor may prescribe thiamine (vitamin B1) before and during treatment and may recommend regular blood tests to monitor your blood counts, liver and kidney function, and thiamine levels.

Common side effects of Inrebic may include diarrhea, nausea, vomiting, fatigue, anemia, and low platelet counts. It can also cause serious thiamine deficiency and a condition called Wernicke's encephalopathy, which may cause confusion, difficulty walking, vision problems, or other neurological symptoms. Contact your doctor immediately if you develop these symptoms, severe vomiting or diarrhea, unusual weakness, or other concerning effects. Before starting treatment, inform your doctor about any medical conditions and all medicines, vitamins, herbal products, and supplements you are taking.

Treatment of Myelofibrosis

Inrebic (Fedratinib) is used to treat adults with intermediate-2 or high-risk primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis. It mainly blocks abnormal JAK2 signaling, which can help reduce an enlarged spleen and improve symptoms associated with myelofibrosis, such as abdominal discomfort, fatigue, bone or muscle pain, itching, and early fullness after eating. By controlling abnormal blood-cell signaling, Fedratinib helps manage the disease and may slow its progression.

Some side effects of Inrebic (Fedratinib) may improve as your body adjusts to the medicine. Consult your doctor if any side effect persists, becomes severe, or causes concern.

Common Side Effects of Inrebic (Fedratinib)

Inrebic (Fedratinib) should be taken exactly as prescribed by your doctor, usually once daily. It may be taken with or without food, although taking it with a meal may help reduce nausea and vomiting. Swallow the capsule whole with water and do not crush, chew, or open it. Your doctor may prescribe thiamine (vitamin B1) before and during treatment and may recommend regular blood tests to monitor your blood counts, liver and kidney function, and thiamine levels.

Inrebic (Fedratinib) is a JAK2 inhibitor that blocks abnormal JAK2 signaling involved in the production and growth of blood cells. By reducing these abnormal signals, Fedratinib helps control the excessive blood-cell production associated with myelofibrosis. This can help reduce spleen enlargement and improve symptoms such as fatigue, abdominal discomfort, bone or muscle pain, itching, and early fullness after eating.

• Keep Inrebic capsules at a temperature below 30°C.
• Store the capsules in the original bottle with the container tightly closed.
• Protect the medicine from moisture during storage.
• Keep the bottle in a safe place that is out of the sight and reach of children.

Alcohol CONSULT YOUR DOCTOR

Consult your doctor before consuming alcohol during treatment with Inrebic (Fedratinib).

Pregnancy CONSULT YOUR DOCTOR

Inform your doctor if you are pregnant or planning to become pregnant. Fedratinib may potentially harm an unborn baby.

Breastfeeding CONSULT YOUR DOCTOR

Consult your doctor before breastfeeding during treatment with Inrebic (Fedratinib).

Driving CONSULT YOUR DOCTOR

Inrebic may cause dizziness, fatigue, or weakness. Avoid driving if these symptoms affect your alertness or ability to drive safely.

Kidney CAUTION

Inform your doctor if you have kidney problems before starting treatment. Your doctor may adjust the dose and monitor kidney function.

Liver CAUTION

Tell your doctor if you have liver problems. Liver function may be monitored during treatment, and dose adjustment may be required.

• Take Inrebic (Fedratinib) exactly as prescribed by your doctor and follow the recommended treatment schedule.
• Take thiamine (vitamin B1) supplements as prescribed and attend regular blood tests to monitor your thiamine levels and overall health.
• Contact your doctor if you experience persistent or severe diarrhea, nausea, or vomiting, as these may lead to dehydration.
• Seek immediate medical attention if you develop confusion, difficulty walking, vision problems, severe weakness, or other signs of thiamine deficiency.
• Inform your doctor about all medicines, vitamins, herbal products, and dietary supplements you are taking to help prevent possible drug interactions.
• Read More About - Inrebic (Fedratinib) from Pharma Five.

Pharma Five, can facilitate patients in importing Inrebic (Fedratinib) in small quantities for personal use. To complete the import process, the applicant must submit an application in Form 12A along with a prescription issued by a Registered Medical Practitioner (RMP).

Pharma Five assists patients seeking Inrebic (Fedratinib) by providing experienced pharmaceutical consultancy and facilitation services for accessing specialized medicines through the appropriate import process. Pharma Five provides extensive pharmaceutical service coverage across India, serving patients and healthcare requirements in prominent cities such as Mumbai, Delhi, Kolkata, Bhubaneswar, Bangalore, Hyderabad, Chennai, Ahmedbad, Pune, Surat, Visakhapatnam, Jaipur, Lucknow, Nagpur, Indore, Patna, Agartala, Guwahati, Imphal, Kohima, Namchi, Noida, Ghaziabad, Ludhiana, Agra, Varanasi, Srinagar, Amritsar, Jodhpur, Chandigarh, Gurgaon, Gorakhpur, Dehradun, Jammu, Hyderabad, Thiruvananthapuram, Kochi, Coimbatore, Puducherry, Mysuru, Salem, Vellore, Tiruppur, Guntur, Goa, Kolhapur, Mumbai, Nashik, and various other regions in India.